Almac Sciences, a member of the Almac Group, today announces a £500,000 investment in NMR instrumentation at its global Headquarters, Craigavon, UK, marking an over £900,000 total investment in nuclear magnetic resonance (NMR) technology for the organisation since 2018.

High-resolution NMR is a key enabling technology that delivers advanced characterisation and purity assessment abilities in line with regulatory requirements. The service helps deliver comprehensive solutions that support drug substance (API) and drug product development programs, from early phase to commercialisation.

Almac’s investment includes the addition of a second 500MHz NMR system, which has been added to further expand the current service offerings within of Almac Sciences’ state-of-the-art cGMP facility. This will boost Almac’s well-established NMR testing service already available to clients, while also increasing through-put, capacity, and speed to enhance efficiency and turnaround times.

The second 500MHz NMR instrument installation at Almac combines Bruker’s cutting-edge Avance Neo platform with a Prodigy Cryoprobe. This set up provides improves capacity to analyse nuclei from 15N to 31P to high sensitivity and resolution, in addition to the running of 2D and quantitative NMR experiments. It also provides additional security for urgent analyses, additional processing capabilities, and superior data integrity controls to ensure increasing regulatory compliance needs are met.

Dr John Malone, Analytical Manager, Almac Sciences said, “The additional NMR technology installation in our cGMP lab allows increased security, flexibility and capacity enabling us to provide an enhanced service to our clients.”

Dr. Darren Thomas, Vice President, Almac Sciences commented “Almac Sciences is committed to ensuring our investments are future-proof and enable us to seamlessly meet our clients’ needs that exist not just today, but in the future. By continuing to invest in NMR service offerings, we’re delighted to offer our clients cutting-edge technology that supports their product safety imperative and accelerates the drug development cycle”

How can we help?